Alaunos Therapeutics, Inc.

TCRT · Nasdaq · United States

Share price · TCRT

$1.72-0.16 (-8.51%) 3M

close as of 2026-11-18 · 24h delayed · vol 52K (0.0x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when TCRT's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 13 Oct 2026+188.6%
  2. 12 Oct 2026+33.6%
  3. 7 Oct 2026+12.9%

    Nothing announced by TCRT that day or the session before.

  4. 2 Oct 2026-10.9%
  5. 18 Sep 2026-25.0%
  6. 17 Sep 2026+25.0%
  7. 16 Sep 2026-9.2%

    Nothing announced by TCRT that day or the session before.

  8. 29 Jun 2026+13.9%
  9. 11 Jun 2026+12.2%
  10. 8 Jun 2026-12.3%

Share of unusual movement by asset

For each asset, the share of TCRT's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Other company news (earnings, financing, releases naming no asset)—60%
Sessions with no dated event—40%

No dated announcements about its assets since 2 Jul 2024.

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Darinaparsin(Darvias)No recent activity
Phase 2
apoptosis via reactive oxygen species (ROS) generation and mitochondrial disruptionSmall molecule
Non-Hodgkin Lymphoma
Peripheral T-Cell Lymphoma

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Quarterly & interim (15)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$0$0.4M$0.1M$0.9M-$0.3M operating cash flowreport ↗
View 14 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q1$0$0.4M$0.3M$1.0M-$1.0M operating cash flowreport ↗
2025-Q3$0$0.5M$1.9M$1.2M-$0.8M operating cash flowreport ↗
2025-Q2$0$0.2M$2.9M$1.1M-$0.7M operating cash flowreport ↗
2025-Q1$0$0.3M$0.3M$1.1M-$0.8M operating cash flowreport ↗
2024-Q3$0$0.1M$1.7M$1.1M-$0.8M operating cash flowreport ↗
2024-Q2$0$0.2M$2.5M$1.1M-$1.7M operating cash flowreport ↗
2024-Q1$0$0.1M$4.1M$1.7M-$1.9M operating cash flowreport ↗
2023-Q3$0$3.7M$12M$8.5M-$6.4M operating cash flowreport ↗
2023-Q2$0$5.2M$18M$8.8M-$7.0M operating cash flowreport ↗
2023-Q1$0$6.5M$37M$10M-$9.4M operating cash flowreport ↗
2022-Q3$2.9M$7.9M$52M$8.8M-$6.1M operating cash flowreport ↗
2022-Q2$0$5.9M$60M$9.9M-$8.2M operating cash flowreport ↗
2022-Q1—$5.6M$68M$9.8M-$7.8M operating cash flowreport ↗
2021-Q3$0.4M$15M$92M$23M-$9.6M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY<$0.1M$1.4M$1.4M$1.1M-$2.9M operating cash flowreport ↗

Alaunos Therapeutics, Inc. reported revenue of $0.01M, up 0.0% YoY, R&D spend of $1.36M, up 277.8% YoY, cash and equivalents of $1.39M, and a net loss of $4.18M for fiscal year 2025.

Figures only: this period's report disclosed no narrative text

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY<$0.1M$0.4M$1.1M$1.2M-$5.0M operating cash flowreport ↗
2023-FY<$0.1M$16M$6.1M$8.8M-$30M operating cash flowreport ↗
2022-FY$2.9M$25M$53M$9.4M-$29M operating cash flowreport ↗
2021-FY$0.4M$50M$76M$20M-$61M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-10-06Jerman Michael Allen · directorAward / grant20,990$0.74$16KForm 4
2026-10-06Postma Robert W · directorAward / grant21,829$0.74$16KForm 4
2026-10-06Weis Holger · CEOAward / grant23,564$0.74$18KForm 4
2026-10-06Vieser Jaime · directorAward / grant22,669$0.74$17KForm 4
2026-08-06Weis Holger · CEOAward / grant4,363$2.01$9KForm 4
2026-07-23Vieser Jaime · directorAward / grant8,789$1.92$17KForm 4
2026-07-23Postma Robert W · directorAward / grant8,463$1.92$16KForm 4
2026-07-23Weis Holger · CEOAward / grant4,568$1.92$9KForm 4